Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and surviva...

Gespeichert in:

Bibliographische Detailangaben
Zeitschriftentitel:	Blood
Personen und Körperschaften:	Choi, Sung W., Kitko, Carrie L., Braun, Thomas, Paczesny, Sophie, Yanik, Gregory, Mineishi, Shin, Krijanovski, Oleg, Jones, Dawn, Whitfield, Joel, Cooke, Kenneth, Hutchinson, Raymond J., Ferrara, James L. M., Levine, John E.
In:	Blood, 112, 2008, 4, S. 1539-1542
Format:	E-Article
Sprache:	Englisch
veröffentlicht:	American Society of Hematology
Schlagwörter:	Cell Biology Hematology Immunology Biochemistry

Details
Zusammenfassung:	<jats:title>Abstract</jats:title> <jats:p>Acute graft-versus-host disease (GVHD) remains a significant cause of mortality after hematopoietic cell transplantation (HCT). Tumor necrosis factor–alpha (TNF-α) mediates GVHD by amplifying donor immune responses to host tissues and by direct toxicity to target organs. We measured TNF receptor 1 (TNFR1) as a surrogate marker for TNF-α in 438 recipients of myeloablative HCT before transplantation and at day 7 after transplantation. Increases in TNFR1 levels more than or equal to 2.5 baseline correlated with eventual development of GVHD grade 2 to 4 (58% vs 32%, P < .001) and with treatment-related mortality (39% vs 17%, P < .001). In a multivariate analysis including age, degree of HLA match, donor type, recipient and donor sex, disease, and status at HCT, the increase in TNFR1 level at day 7 remained a significant predictor for outcome. Measurement of TNFR1 levels early after transplantation provides independent information in advance of important clinical outcomes, such as GVHD and death.</jats:p>
Umfang:	1539-1542
ISSN:	0006-4971 1528-0020
DOI:	10.1182/blood-2008-02-138867